Get the Stockscreener App
106.60
0.48%
0.51
After Hours:
108.46
1.86
+1.74%
Rhythm Pharmaceuticals Inc stock is traded at $106.60, with a volume of 773.29K.
It is up +0.48% in the last 24 hours and up +11.24% over the past month.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
See More
Previous Close:
$106.09
Open:
$104.92
24h Volume:
773.29K
Relative Volume:
0.99
Market Cap:
$7.31B
Revenue:
$217.17M
Net Income/Loss:
$-202.68M
P/E Ratio:
-46.29
EPS:
-2.3028
Net Cash Flow:
$-156.63M
1W Performance:
-1.66%
1M Performance:
+11.24%
6M Performance:
+4.89%
1Y Performance:
+17.56%
1-Day Range:
$104.20
$108.40
1-Week Range:
$104.20
$110.69
52-Week Range:
$74.50
$122.20
Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile
Name
Rhythm Pharmaceuticals Inc
Sector
Industry
Phone
857-264-4280
Address
222 BERKELEY STREET, BOSTON, MA
Compare RYTM vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RYTM
Rhythm Pharmaceuticals Inc
|
106.60 | 7.28B | 217.17M | -202.68M | -156.63M | -2.3028 |
VRTX
Vertex Pharmaceuticals Inc
|
485.65 | 123.36B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.69 | 71.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
860.55 | 53.68B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
186.16 | 38.09B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
267.47 | 37.80B | 4.29B | 577.22M | 641.34M | 4.2086 |
Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-19-26 | Initiated | RBC Capital Mkts | Outperform |
| Nov-25-25 | Initiated | Citigroup | Buy |
| Nov-05-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-10-25 | Initiated | Goldman | Buy |
| Jul-07-25 | Initiated | Leerink Partners | Outperform |
| Apr-07-25 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-05-25 | Resumed | Stifel | Buy |
| Jan-02-25 | Initiated | Jefferies | Buy |
| Dec-20-24 | Initiated | Oppenheimer | Outperform |
| Oct-21-24 | Initiated | Guggenheim | Buy |
| Sep-18-24 | Initiated | H.C. Wainwright | Buy |
| Sep-17-24 | Initiated | JMP Securities | Mkt Outperform |
| May-08-24 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-19-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-01-23 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-18-23 | Resumed | Canaccord Genuity | Buy |
| Aug-08-22 | Upgrade | Goldman | Neutral → Buy |
| Aug-05-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-17-22 | Reiterated | Needham | Buy |
| Mar-02-22 | Resumed | Stifel | Buy |
| Feb-17-22 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-14-21 | Resumed | Goldman | Neutral |
| Aug-04-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Aug-04-21 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Nov-30-20 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-08-20 | Initiated | Goldman | Sell |
| Jul-12-19 | Upgrade | Stifel | Hold → Buy |
| Jul-08-19 | Initiated | Canaccord Genuity | Buy |
| Mar-13-19 | Initiated | Ladenburg Thalmann | Buy |
| Sep-07-18 | Resumed | Morgan Stanley | Overweight |
| Jun-25-18 | Reiterated | Needham | Buy |
| Jun-15-18 | Reiterated | Needham | Buy |
| Oct-30-17 | Initiated | BofA/Merrill | Buy |
| Oct-30-17 | Initiated | Needham | Buy |
View All
Rhythm Pharmaceuticals Inc Stock (RYTM) Latest News
Law firm probes Rhythm Pharmaceuticals officers for possible self-dealing harming shareholders - Pluang
Kuehn Law Encourages Investors of Rhythm Pharmaceuticals, Inc. to Contact Law Firm - GlobeNewswire Inc.
symbol__ Stock Quote Price and Forecast - CNN
Enterprise value to revenue forward of Rhythm Pharmaceuticals, Inc. – BMV:RYTM - TradingView
Does NEJM-Validated TRANSCEND Data on Setmelanotide Reshape the Bull Case for Rhythm Pharmaceuticals (RYTM)? - Sahm
Rhythm Pharmaceuticals (RYTM) Edges Higher, Nears Key Resistance LevelSymmetrical Triangle - dars.gov.et
Citizens reiterates Rhythm Pharmaceuticals stock rating on strong Imcivree launch data - Investing.com Canada
Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis: Exploring a 28.91% Upside Potential in Biotechnology - DirectorsTalk Interviews
Enterprise value to EBITDA forward of Rhythm Pharmaceuticals, Inc. – NASDAQ:RYTM - TradingView
Price to earnings forward of Rhythm Pharmaceuticals, Inc. – NASDAQ:RYTM - TradingView
Price-Driven Insight from (RYTM) for Rule-Based Strategy - Stock Traders Daily
Enterprise value to revenue forward of Rhythm Pharmaceuticals, Inc. – XETR:1RV - TradingView
Rhythm Pharmaceuticals (RYTM) On TRANSCEND And New Approvals, Buying Opportunity Or Priced In? - Sahm
Rhythm Pharmaceuticals Inc. announced that the results of its Phase 3 Transcend clinical trial for acquired hypothalamic obesity have been published in the top international medical journal, The New England Journal of Medicine. - Bitget
Rhythm Pharmaceuticals Announces NEJM Publication of Phase 3 TRANSCEND Trial Results for Setmelanotide in Acquired Hypothalamic Obesity - Quiver Quantitative
Rhythm Pharmaceuticals Announces The New England Journal of - GlobeNewswire
Rhythm Pharmaceuticals Announces The New England Journal of Medicine Publication of Phase 3 TRANSCEND Trial Results in Acquired Hypothalamic Obesity - Yahoo Finance UK
CCORF Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $151 - Moomoo
RYTM Maintained by RBC Capital -- Price Target Raised to $141.00 - GuruFocus
Rhythm Pharmaceuticals balances obesity-drug growth prospects and biotech risks - Ad-hoc-news.de
RBC Capital Adjusts Rhythm Pharmaceuticals Price Target to $141 From $137, Maintains Outperform Rating - marketscreener.com
Rhythm Pharmaceuticals Announces New Data Presentations In Acquired Hypothalamic Obesity At Pediatric Endocrine Society >RYTM - Moomoo
Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis: A Biotech Contender with 22% Upside Potential - DirectorsTalk Interviews
Price to sales forward of Rhythm Pharmaceuticals, Inc. – NASDAQ:RYTM - TradingView
RYTMRhythm Pharmaceuticals Inc Options - Finviz
Rhythm Pharmaceuticals announces public offering of common stock - MSN
Rhythm Pharmaceuticals Inc to Discuss Interim Six-Month Phase 2 Results Evaluating Setmelanotide Call Transcript - GuruFocus
Rhythm Pharmaceuticals (RYTM) CSO exercises RSUs, 2,150 shares withheld for taxes - Stock Titan
Rhythm Pharmaceuticals Stock On Fire: Up 28% With 12-Day Winning Streak - Trefis
Rhythm Pharmaceuticals stock trades up to $111.03 as Rhythm Pharmaceuticals closes offices for July 4th break - Traders Union
Rhythm Pharmaceuticals Stock Surges 28%, With A 12-Day Winning Spree - Trefis
Is Rhythm Pharmaceuticals, Inc. (RYTM) Stock Poised for Growth After Encouraging Setmelanotide Trial Results? - Insider Monkey
Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis: A Biotech with Promising Upside and Strong Buy Ratings - DirectorsTalk Interviews
Rhythm Pharmaceuticals Stock Rockets 28% With 11-Day Winning Streak - Trefis
(RYTM) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Rhythm Pharmaceuticals highlights obesity pipeline, shares track sector peers - Ad-hoc-news.de
Rhythm Pharmaceuticals Stock On Fire: Up 26% With 10-Day Winning Streak - Trefis
Rhythm Pharmaceuticals 8-K Filing June 2026 – Company Details, Nasdaq Listing, and Executive Information - Minichart
Form 4 Rhythm Pharmaceuticals Inc For: 25 June By Investing.com - Investing.com South Africa
Rhythm Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director JEAN CHRISTOPHE - Moomoo
Rhythm Pharmaceuticals (RYTM) director receives RSUs, options and converts 4,712 RSUs - Stock Titan
[Form 4] RHYTHM PHARMACEUTICALS, INC. Insider Trading Activity - Stock Titan
Rhythm Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director MCGIRR DAVID W J - Moomoo
Director at Rhythm Pharmaceuticals (RYTM) receives new RSUs, options and exercises units - Stock Titan
Rhythm Pharmaceuticals (RYTM) director granted RSUs, stock options and converts RSUs to shares - Stock Titan
Rhythm Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Arbuckle Stuart A - Moomoo
Rhythm Pharmaceuticals (RYTM) director granted RSUs, options and new shares - Stock Titan
Rhythm Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director GOOD JENNIFER L - Moomoo
Rhythm Pharmaceuticals (NASDAQ: RYTM) holders approve directors, pay and Ernst & Young - Stock Titan
Rhythm Pharmaceuticals | 8-K: Current report - Moomoo
Rhythm Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:RYTM) - TradingView
Rhythm Pharmaceuticals Inc Stock (RYTM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Rhythm Pharmaceuticals Inc Stock (RYTM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| TETRAULT LYNN A. | Director |
Jun 22 '26 |
Sale |
100.32 |
37,000 |
3,711,896 |
7,000 |
0.80%
2.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):